BioSpace News Archive

An umbrella protects the human brain from negative influences. Art collage.

Psychedelics

Psychedelics Space Enters New Era as AbbVie Dives In

With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space has soundly rebounded from Lykos’ rejection last year. There are now seven programs in Phase III trials across the sector, with multiple companies vying for that first approval.

September 22, 2025

·

6 min read

·

Heather McKenzie

Illustration showing hands connecting mechanism gears

PARTNERED

Staying Agile: Blended Workforces Offer Strategic Approach to Business Needs

Building and scaling biopharma workforces can go beyond recruiting permanent employees to include fractional workers and consultants. A Slone Partners executive discusses how these blended workforces operate, highlighting the strategic benefits.

September 22, 2025

·

4 min read

·

BioSpace Insights

Cairo, Egypt, October 31 2024: Novartis CO building in Egypt, Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland, manufactures the drugs

Drug pricing

Novartis Looking for Constructive Ways To Bring Down Drug Costs in US

In an interview with German-language outlet Neue Zuercher Zeitung, Novartis CEO Vas Narasimhan said the company is exploring ways to remove or minimize the drug price gap between the U.S. and its other markets in similarly developed countries.

September 22, 2025

·

2 min read

·

Tristan Manalac

Black swan theory or a black swan event is a term used to describe a very rare or otherwise unexpected event that has a major effect, such as a financial crash or pandemic. The term is based on an ancient saying which presumed black swans did not exist.

Rare diseases

Rare Disease Experts See Futility in FDA’s Proposed Framework

The FDA’s proposed Rare Disease Evidence Principles review process is a starting point for getting rare disease therapies across the finish line, but industry leaders say there are more concrete steps the regulator could take to help patients.

September 22, 2025

·

5 min read

·

Dan Samorodnitsky

Feb 2, 2020 South San Francisco / CA / USA - Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company

Cancer

As Exclusivity Loss Looms, Merck Wins Subcutaneous Approval for Keytruda

For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent protections expiring in 2028.

September 22, 2025

·

2 min read

·

Tristan Manalac

Pictured: Entrance to Pfizer's office in Belgium

Mergers & acquisitions

Pfizer Stages Obesity Comeback With $4.9B Metsera Acquisition

The acquisition of breakout obesity star Metsera should pump new life into Pfizer’s portfolio, which over the last two years has suffered from three discontinued assets.

September 22, 2025

·

2 min read

·

Tristan Manalac

Pictured: Blue Sanofi sign on building in Germany at night

Multiple sclerosis

FDA Action Date for Sanofi’s Oral Multiple Sclerosis Drug Bumped to December

The company was expecting a decision from the FDA by Sept. 28 for its oral drug tolebrutinib, but an update to the drug’s application package convinced the agency to take more time to review.

September 22, 2025

·

1 min read

·

Dan Samorodnitsky

Press Releases

Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy

September 22, 2025

·

9 min read

Press Releases

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed